Avantor (NYSE:AVTR) Given New $23.00 Price Target at Barclays

Avantor (NYSE:AVTR) had its price target reduced by Barclays from $26.00 to $23.00 in a research note published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms have also recently commented on AVTR. UBS Group reissued a “neutral” rating and set a $25.00 target price (down previously from $29.00) on shares of Avantor in a research note on Friday, January 17th. Wells Fargo & Company cut their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Raymond James cut their target price on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Finally, Robert W. Baird cut their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $26.15.

Avantor Stock Down 1.8 %

AVTR opened at $18.06 on Monday. Avantor has a fifty-two week low of $18.00 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The company has a fifty day moving average of $21.63 and a two-hundred day moving average of $23.39. The stock has a market capitalization of $12.29 billion, a price-to-earnings ratio of 39.26, a PEG ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the previous year, the business earned $0.22 earnings per share. On average, research analysts expect that Avantor will post 0.98 earnings per share for the current year.

Institutional Investors Weigh In On Avantor

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Louisiana State Employees Retirement System increased its holdings in shares of Avantor by 0.3% in the fourth quarter. Louisiana State Employees Retirement System now owns 188,900 shares of the company’s stock valued at $3,980,000 after purchasing an additional 500 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Avantor by 2.1% in the third quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock valued at $644,000 after purchasing an additional 503 shares during the last quarter. Blue Trust Inc. grew its position in Avantor by 6.9% in the fourth quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock worth $170,000 after acquiring an additional 522 shares during the period. Pacer Advisors Inc. grew its position in Avantor by 0.5% in the fourth quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock worth $2,103,000 after acquiring an additional 542 shares during the period. Finally, Veracity Capital LLC grew its position in Avantor by 1.0% in the third quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after acquiring an additional 543 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.